As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…
HOME > BUSINESS
BUSINESS
- Otsuka to Set Up Joint Venture Company to Develop, Commercialize Pancreatic Islet Cells
October 20, 2011
- Growell to Introduce T-Point Service for Copayments of Ethical Drugs
October 20, 2011
- Sanofi Signs Comprehensive Contract with Kyoto Univ. on Life Science Research
October 19, 2011
- Takeda Initiates PIII Clinical Trials for Antidiabetic TAK-875 in US, Europe
October 19, 2011
- JT to Cease Development of Osteoporosis Treatment following Termination of License Agreement with Merck
October 19, 2011
- SSP Aims for 10% Market Share with Switch OTC Alesion 10
October 19, 2011
- UCB Japan Reorganizes Sales & Marketing Division to Enhance Specialization
October 19, 2011
- Japan, a Strategic Country Where Growth is Expectable: New AZ President Hudson
October 18, 2011
- MTPC Aims at Sales of ¥500 Bil. in FY2015
October 18, 2011
- MTPC Aims to Initiate Clinical Studies for 3 Compounds per Year
October 18, 2011
- Torii Upwardly Revises Profit Forecast for 1st Half of FY2012
October 18, 2011
- Eisai, Johns Hopkins Univ. Agree on Neurological Drug Discovery Collaboration
October 18, 2011
- OncoTherapy Science to Start Clinical Trial for Cancer Treatment Antibody in France
October 18, 2011
- Takeda Appoints Davidsen Head of Emerging Markets, Nycomed
October 18, 2011
- R-Tech Ueno to Resume Development of Treatment for Dry Eye
October 18, 2011
- NBI, Eli Lilly Japan to Establish “Special Position” for Trazenta in DPP-4 Inhibitor Market
October 18, 2011
- US MediciNova to Jointly Conduct Clinical Trials of MN-221 with Kissei
October 17, 2011
- Bayer, Onyx Restructure Global Oncology Partnership
October 17, 2011
- Ube, Santen Enter into License Agreement for EP2 Agonist
October 17, 2011
- MTPC Licenses Novel Pruritus Treatment from Toray in North America
October 17, 2011
ページ
Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…